We’re pleased to announce a new SRF-funded research study: Establishing a Spatially–integrated Transcriptomic, Epigenomic, and Histologic Signature of Fibrosis in Systemic Sclerosis, led by Michael Longaker, MD, and Howard Chang, MD, PhD from Stanford University School of Medicine.
By utilizing newly developed ways to examine fibrotic tissues, Drs. Longaker and Chang will gain an understanding of fibrosis that is unprecedented in its scale and depth. These technologies will also give researchers new insights into potential therapies that can reduce or prevent this burden for patients.
The SRF is committed to identifying and funding the most promising, highest-quality scleroderma research that will drive scientific discoveries forward.